article thumbnail

Investors put $400M into biotech licensing obesity drugs from China

BioPharma Drive: Drug Pricing

The biotech, tentatively named Hercules CM Newco, has rights to three incretin drugs discovered by Jiangsu Hengrui Pharmaceuticals, two of which are in clinical testing.

Licensing 356
article thumbnail

How to Identify Branded Drugs with a Low Likelihood of Generic Entry as Targets for In-Licensing

Drug Patent Watch

Identifying branded drugs with a low likelihood of generic entry has become a crucial strategy for companies looking to expand their product portfolio through in-licensing. This approach not only helps maintain market exclusivity but also ensures a steady revenue stream for pharmaceutical companies.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Benefits of Drug Patent Licensing Agreements

Drug Patent Watch

The Power of Patent Licensing: Unlocking Innovation and Access to Medicines Patent licensing agreements have become a crucial tool in the pharmaceutical industry, allowing companies to collaborate and…

Licensing 101
article thumbnail

Merck bets $200M on a new type of heart pill

BioPharma Drive: Drug Pricing

A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a genetic risk factor called lipoprotein(a).

Licensing 213
article thumbnail

Effective Drug Patent Prosecution Strategies: Securing Your Pharmaceutical Innovations

Drug Patent Watch

As a business professional in the pharmaceutical industry, understanding and implementing effective strategies for drug patent prosecution can be the difference between market domination and missed opportunities. Dr. Jane Smith, a patent attorney specializing in pharmaceuticals, advises: “File early and file often. billion[1].

article thumbnail

How do patent thickets vary across different countries

Drug Patent Watch

“Patent thickets can lead to holdup of innovations, increases in the complexity of negotiations over licenses and increases in litigation, and can also create incentives to add more and weaker patents to the patent system. Cross-licensing agreements: To navigate patent thickets, many companies enter into cross-licensing agreements.

article thumbnail

Using DrugPatentWatch to Support Out-Licensing and Partnering Decisions

Drug Patent Watch

"Unlocking the Secrets to Smarter Partnerships: How One Tool is Revolutionizing the Way Pharma Companies Approach Out-Licensing and Partnering Decisions As the pharmaceutical industry continues to evolve, companies are under increasing pressure to maximize their portfolios and minimize risk.